AntibodySystem는 Primary Antibody Biosimilar - Research Grade 

제품을 전문적으로 생산하는 20년의 경험이 있는 High Quality 제조사입니다. 

제품 설명 

Anti-Trastuzumab ELISA Kit

제품 번호

KAC09601

제품 특징

Catalog No.

KAC09601

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative sandwich enzyme immunoassay technique. Trastuzumab has been pre-coated onto a microplate. Samples or standards are pipetted into microwells and Anti-Trastuzumab will be captured by immobilized Trastuzumab. After washing away any unbound substances, a biotin-labeled Trastuzumab is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Anti-Trastuzumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

3.13 - 200 ng/mL

Sensitivity

2.94 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <10%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <15%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

Alternative Names

timigutuzumab, 4D5-8, 4D5V8, Herceptin, rhuMab HER2,CAS: 180288-69-1

Data Image

• 

  Experiment Example
  CALCULATION OF RESULTS
  Average the duplicate readings for each standard and sample. Construct a standard curve by plotting the mean absorbance for each standard on the Y-axis against the concentration on the X-axis and draw a best fit curve through the points on the graph. The data may be linearized by plotting the log of the Anti-Trastuzumab concentrations versus the log of the O.D. and the best fit line can be determined by regression analysis. This procedure will produce an adequate but less precise fit of the data. If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.

References

Medicare spending and use of subcutaneous biologic formulations with hyaluronidase., PMID:40515473

Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study., PMID:40514709

Pharmacokinetic bioequivalence of the fixed-dose combination of pertuzumab and trastuzumab administered subcutaneously using a handheld syringe or an on-body delivery system., PMID:40514611

Drug-drug interaction between trastuzumab emtansine (T-DM1) and orally administered tacrolimus in a patient and in rats., PMID:40513507

ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial., PMID:40512191

Advancing Antibody-Drug Conjugates: Precision Oncology Approaches for Breast and Pancreatic Cancers., PMID:40507272

Preirradiation of Spheroids with 225Ac-Trastuzumab Improves Penetration of 225Ac-Liposomes and MIRDcell Predictions of Responses to Drug Cocktails., PMID:40506236

[Effect of taste perception on nutritional status in patients with breast cancer: a systematic review]., PMID:40504002

Plasma IFN-γ may predict pyrotinib efficacy in patients with HER2-positive advanced breast cancer., PMID:40502358

Comparative pharmacological analysis of fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy: Two recently developed chemotherapies in the crucial battle against breast cancer., PMID:40502326

Reply to Letter to the Editor: 'A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases' by Y. Liu & C. Zhang., PMID:40500685

Strong Hsp90α/β Protein Expression in Advanced Primary CRC Indicates Short Survival and Predicts Response to the Hsp90α/β-Specific Inhibitor Pimitespib., PMID:40498011

Beyond the Tumor: Invasive Fungal Infection Unveiled in HER2-Positive Breast Cancer Patient Mimicking Disease Relapse., PMID:40496029

Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06., PMID:40494041

Long and short-term efficacy and safety comparison of nab-paclitaxel versus paclitaxel combined with trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer: A systematic review and meta-analysis., PMID:40493995

Advanced 64Cu/67Cu-Based Theranostics: Application of the Copper Chelator TE1PA to a Murine Model of HER2-Positive Gastric Cancer., PMID:40493435

Effects of concurrent HER2-directed therapy on development of cerebral radionecrosis after stereotactic radiotherapy: a systematic review., PMID:40493045

Novel Quaternary Ammonium Salt-Linked STING Agonist Antibody-Drug Conjugate: Synergistic Activation of Tumor Immunity with Mitigated Off-Target Toxicity., PMID:40492586

Reinforced Polymer-Nanoparticle Hydrogels for Subcutaneous and Sustained Delivery of Trastuzumab., PMID:40489148

A Randomized Phase 2 Study of Neratinib With or Without Fulvestrant for Patients With HER2-Positive, Estrogen Receptor-Positive Metastatic Breast Cancer., PMID:40484776

Treatment of breast cancer in a patient with sickle cell disease., PMID:40484435

Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study., PMID:40483197

Advancing Neoadjuvant Therapy with Inetetamab for HER2-Positive Breast Cancer., PMID:40482910

Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers., PMID:40480221

Spatial discovery of pyrotinib overcoming HER2-positive breast cancer resistance by breaking fibroblast-induced immune barriers., PMID:40480079

The role of HER2-targeted therapy in urothelial carcinomas., PMID:40478157

Site-Specific Immune and Stromal Architecture Drive Resistance to Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer., PMID:40475468

Design, Synthesis, and Biological Evaluation of Evodiamine Derivatives as Antibody-Drug Conjugate (ADC) Payloads., PMID:40474320

225Ac α-Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2-Expressing Breast Cancer., PMID:40473462

Quantitative [89Zr]Zr-Trastuzumab PET and Diffusion- Weighted MRI for Characterization of Metastatic HER2-Positive Breast Cancer with PET/MRI., PMID:40473459

Maintenance with niraparib in patients with stage III, stage IV, chemo-naïve recurrent or platinum-sensitive recurrent uterine serous carcinoma: study protocol for a phase II clinical trial., PMID:40473279

Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China., PMID:40472040

Trastuzumab-deruxtecan shows interesting disease control in a multitreated patient with ERBB2 amplified parotid carcinoma, a case report., PMID:40470107

Trastuzumab monotherapy as maintenance treatment for metastatic HER2+ vulvar Paget disease: systematic review and case report., PMID:40469473

TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis., PMID:40468999

Successful Treatment of HER2 V659E Mutation-Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report., PMID:40468744

Continuous glucose monitoring to characterize hyperglycemia during chemotherapy for early stage breast cancer., PMID:40468140

Improving the Therapeutic Selectivity of Trastuzumab Deruxtecan Using 8C2 Fab Fragments., PMID:40467988

Adverse effect of trastuzumab deruxtecan in solid tumours: a systematic review and meta-analysis., PMID:40466817

Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer., PMID:40464376

The radioactive 103Pd and 109Pd palladium bipyridyl-bisphosphonate complexes for radionuclide therapy of bone metastatic tumor cells., PMID:40463346

Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II Study., PMID:40461387

Mechanisms of resistance to antibody-drug conjugates in cancers., PMID:40460510

New Treatment Approaches for Triple-Negative Breast Cancer., PMID:40460322

Superhydrophilic Multichannel TiO2 Fibers for Simultaneous Enrichment of O-GalNAc Glycopeptides and Phosphopeptides., PMID:40460305

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer., PMID:40454632

The Rapidly Evolving Landscape of Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Endometrial Carcinoma and Other Gynecologic Malignancies., PMID:40452624

Radionuclide-Aided Improvement of the Therapeutic Efficacy of Novel Antibody-Drug Conjugates against HER2-Expressing Cancers., PMID:40448644

EXPRESS: Advanced Therapies for Stomach Cancer., PMID:40448345

Radiobioconjugate of Kadcyla with Radioactive Gold Nanoparticles for Targeted Therapy of HER2-Overexpressing Cancers., PMID:40443068

AntibodySystem의 모든 제품들을 만나 보세요!  

Products

Recombinant Protein

Antibody

Assay Kit

Research Biosimilar

Enzyme

Trending Product

Super-Affinity Antibody

Cell Lysates

Antibodysystem - Official Distributor in South Korea "Morebio" 한국 독점 대리점 "모아바이오"